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The K/BxN serum-transfer arthritis (STA) model is a murine model in which the immu-
nological mechanisms occurring in rheumatoid arthritis (RA) and other arthritides can be 
studied. To induce K/BxN STA, serum from arthritic transgenic K/BxN mice is transferred 
to naive mice and manifestations of arthritis occur a few days later. The inflammatory 
response in the model is driven by autoantibodies against the ubiquitously expressed 
self-antigen, glucose-6-phosphate isomerase (G6PI), leading to the formation of immune 
complexes that drive the activation of different innate immune cells such as neutrophils, 
macrophages, and possibly mast cells. The pathogenesis further involves a range of 
immune mediators including cytokines, chemokines, complement factors, Toll-like 
receptors, Fc receptors, and integrins, as well as factors involved in pain and bone 
erosion. Hence, even though the K/BxN STA model mimics only the effector phase of 
RA, it still involves a wide range of relevant disease mediators. Additionally, as a murine 
model for arthritis, the K/BxN STA model has some obvious advantages. First, it has a 
rapid and robust onset of arthritis with 100% incidence in genetically identical animals. 
Second, it can be induced in a wide range of strain backgrounds and can therefore 
also be induced in gene-deficient strains to study the specific importance of disease 
mediators. Even though G6PI might not be an essential autoantigen, for example, in 
RA, the K/BxN STA model is a useful tool to understand how autoantibodies, in general, 
drive the progression of arthritis by interacting with downstream components of the 
innate immune system. Finally, the model has also proven useful as a model wherein 
arthritic pain can be studied. Taken together, these features make the K/BxN STA model 
a relevant one for RA, and it is a potentially valuable tool, especially for the preclinical 
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screening of new therapeutic targets for RA and perhaps other forms of inflammatory 
arthritis. Here, we describe the molecular and cellular pathways in the development 
of K/BxN STA focusing on the recent advances in the understanding of the important 
mechanisms. Additionally, this review provides a comparison of the K/BxN STA model 
to some other arthritis models.
Keywords: K/BxN serum-transfer arthritis model, immune complex-driven arthritis, animal model, autoantibodies, 
rheumatoid arthritis
iNTRODUCTiON
Research into the pathogenesis of rheumatoid arthritis (RA) has 
benefited enormously from a vast number of animal models, 
wherein mechanisms governing arthritis can be studied. These 
include both spontaneous models, such as the tumor necrosis 
factor (TNF) transgenic and interleukin-1 (IL-1) receptor antag-
onist-deficient mice, as well as induced models, most notably the 
collagen-induced arthritis (CIA) model.
In 1996, the K/BxN model of arthritis was reported for the first 
time by the Mathis/Benoist laboratory (1). This model was dis-
covered by crossing T-cell receptor (TCR) transgenic KRN mice 
on a C57BL/6 background (transgenic for a TCR) recognizing a 
bovine ribonuclease peptide (RNase 43–56) presented by I-Ak 
major histocompatibility complex (MHC) class II molecule with 
autoimmune-prone non-obese diabetic (NOD) mice. Surprisingly, 
the F1-generation, called K/BxN mice, developed severe arthritis 
by the age of 4–5 weeks, which rapidly evolved until mobility was 
significantly suppressed (1). Arthritis progression in the K/BxN 
mice is driven by activation of T cells expressing the KRN TCR 
that recognizes a self-peptide bound to the NOD-derived I-Ag7 
molecule on MHC class II antigen-presenting cells (APCs). The 
peptide recognized by the K/BxN TCR, in the context of I-Ag7, 
is the ubiquitously expressed self-antigen, glucose-6-phosphate 
isomerase (G6PI) (2), a cytosolic glycolytic enzyme catalyzing 
the inter-conversion of d-glucose-6-phosphate and d-fructose-
6-phosphate (3). It was demonstrated that the activated T cells 
subsequently interact with B cells through TCR:Ag7–MHC class 
II molecules and CD40:CD40L engagement, thereby promoting 
polyclonal B-cell activation and T-helper cell-dependent produc-
tion of disease-inducing immunoglobulins (IgGs) (1, 3–5).
Importantly, it was further shown that transfer of purified 
IgGs or serum from arthritic K/BxN mice led to a robust and 
reproducible arthritis in many mouse strains, such as BALB/c, 
C57BL/6, and DBA/1 mice (6), as well as B-cell- and lymphocyte-
deficient mice (4). Since transfer of K/BxN sera leads to reproduc-
ible disease in several mouse strains, it is an ideal model to study 
the effector mechanisms involved in progression of disease. As 
expected, arthritis induced by serum transfer is transient and 
wanes after 15–30 days but can be made persistent by repeated 
administration of antibody or serum (4). Overall, the discovery 
of K/BxN arthritis showed that joint-specific disease can be the 
consequence of systemic self-reactivity. The ability to transfer 
arthritis using pooled K/BxN sera has been widely used by many 
researchers to dissect several important effector pathways of 
arthritis in  vivo. In the following sections, current knowledge 
about the K/BxN serum-transfer arthritis (STA) model is 
addressed, with focus on driver mechanisms responsible for 
progression of arthritis after serum transfer. Since B- and T-cells 
are not thought to play a major role in mediating arthritis after 
serum transfer they are not addressed in detail.
Since its discovery in 1996, the model has been used increas-
ingly. From 2000 to 2005, only 15 papers were published about 
the K/BXN STA model (pubmed.com search under “KBxN 
serum transfer arthritis”); from 2005 to 2010, 53 papers were 
published, and from 2010 to 2015, the number was 87 with 18 
papers published in 2015. Nonetheless, a thorough review of the 
literature about the model has not been published since 2004 (3). 
In addition to updating the literature on the K/BxN STA model, 
this review discusses the relevance of the model in relation to RA 
and provides a comparison to other RA models. It should also 
be noted that immune complexes (ICs) have been implicated in 
other arthritides, such as systemic lupus erythematosus (7) and 
ankylosing spondylitis (8); thus, though the focus on this review 
is on RA, it could also be relevant to other arthritides.
THe iNiTiATiON PHASe OF THe K/BxN 
STA MODeL
The main features of what we have termed for convenience, albeit 
somewhat arbitrary, the “initiation phase” of the K/BxN STA 
model, are depicted in the literature-based schematic in Figure 1 
and summarized below.
immune Complexes
To address why the autoimmune inflammatory attack against the 
ubiquitously expressed enzyme, G6PI, occurs only in the distal 
joints, it was first shown that G6PI was present on the articular 
surface in ankle joints in normal mice and, most importantly, that 
its expression was amplified in arthritic mice (9). Second, it was 
demonstrated that purified anti-G6PI IgGs localized specifically 
to the distal joints in the front and rear limbs within minutes of 
intravenous injection, while control IgGs could not be detected 
in any joints. Binding of anti-G6PI IgGs reached saturation after 
20 min and remained localized within the joints for at least 24 h 
(10). This led to the conclusion that anti-G6PI antibodies bind 
directly to extracellular G6PI in normal non-inflamed mouse 
joints, thereby forming anti-G6PI/G6PI ICs directly on the 
cartilage surface. The importance of these ICs was emphasized 
by the observation that pathogenicity after transfer of a pool of 
anti-G6PI monoclonal antibodies (mAb) was directly dependent 
on their ability to form mAb/G6PI ICs (11). Furthermore, it 
was demonstrated that soluble ICs, formed between anti-G6PI 
FiGURe 1 | The “initiation phase” of the K/BxN STA model. A summary of some of the literature on the early stages of K/BxN STA progression, leading to the 
formation of anti-G6PI/G6PI ICs in the joint, is depicted. (1) In the blood, the anti-G6PI antibodies (Ab) bind to G6PI and form the ICs. (2) On neutrophils, for 
example, the ICs bind to Fcγ-receptors (FcγR) triggering the release of vasoactive mediators and the local increase in vascular permeability, thus allowing ICs and 
anti-G6PI Abs to enter the perivascular tissue in the joint. (3) In the perivascular tissue, the ICs might bind to FcγRs on mast cells causing them to degranulate, 
resulting in enhanced vascular permeability. (4) ICs, anti-G6PI Abs, non-specific Abs (not shown) and serum proteins (not shown) enter the joint cavity, where (5) 
anti-G6PI Abs bind to G6PI expressed on the cartilage surface.
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antibodies and G6PI in serum, played a central role in facilitat-
ing access for antibodies to the distal joints by binding to Fcγ-
receptor (FcγR) III (12) possibly expressed on neutrophils in the 
blood (12, 13) (see also Fc Receptors below) but probably also on 
radio-resistant cells in an organ distant from the joint (14). It was 
further suggested that the activation of neutrophils subsequently 
triggers the release of vasoactive mediators, which leads to a local 
increase in vascular permeability, thus allowing ICs to enter the 
perivascular tissue in the joint and possibly bind to FCγRIII on 
mast cells found in close proximity to the microvasculature in 
the synovium (12). If this occurs, it would cause mast cells to 
degranulate, which results in an even larger and more widespread 
increase in the vascular permeability, thus allowing anti-G6PI 
antibodies, non-specific antibodies, and serum proteins to enter 
the joint. Once in the joint, the anti-G6PI antibodies bind to G6PI 
expressed on the articular cartilage surface and thereby mediate 
activation of different components of the innate immune system, 
for example, neutrophils (12) (discussed in Figure 2 below).
It is difficult to explain why ICs in serum facilitate access of 
antibodies exclusively to the distal joints, but it was suggested that 
arthritogenic antibodies cause an increase in the macromolecular 
vasopermeability in sites destined to develop arthritis (14). This 
increased vascular leakage in the distal joints mediated by anti-
G6PI:G6PI ICs seemed to involve vasoactive amines, histamine, 
and serotonin. An increased vasopermeability was also induced 
by G6PI-non-specific ICs. However, the non-specific ICs did not 
promote arthritis development, indicating that simple access to 
the joint is not pathogenic, but there must be a targeting of ICs to 
some joint structures, for example, G6PI expressed on cartilage, 
to induce arthritis (14). Thus, it appears for reasons unknown that 
the distal extremities are especially prone to respond to systemic 
circulating ICs by vascular leakage, which subsequently facilitates 
access of arthritis-inducing antibodies into the joint.
Fc Receptors
An important link between antibodies and activation of the 
immune system is Fc receptors. Four types of murine FcγR have 
been identified. FcγRI, FcγRIII, and FcγRIV mediate activating 
signals via the common γ-chain when cross-linked with ICs, 
while FcγRII inhibits cellular activation upon ligation (15). The 
role of the different FcγRs in the K/BxN STA model was explored 
using knockout (KO) mice. FcγR KO mice were protected from 
arthritis demonstrating the crucial role of FcγRs in this model 
(16). Lack of FcγRI had no influence on arthritis development 
(16), whereas FcγRIII-deficient mice developed reduced arthritis 
with delayed onset (13, 16, 17). The importance of FcγRIV was 
demonstrated by Mancardi et al. (18), who showed that blockade 
of FcγRIV with anti-FcγRIV mAb prevented development of 
arthritis. Additionally, it has been demonstrated that mice with 
a specific deletion of FcγRIV on osteoclasts were protected from 
arthritis induced by K/BxN serum suggesting an important 
role for FcγRIV in maturation and activation of osteoclasts and 
FiGURe 2 | The “effector phase” of the K/BxN STA model. A summary of some of the literature on the subsequent stages of K/BxN STA progression, driven by 
joint-localized anti-G6PI/G6PI ICs and their proposed interaction with innate immune cells, such as neutrophils and macrophages, is depicted. (1) The alternative 
complement pathway is activated by the ICs, leading to C3 cleavage and eventually to the generation of C5a. Subsequently, C5a activates neutrophils via C5aR, 
which leads to their release of LTB4. (2) Activation of neutrophils by the LTB4/BLT1 interaction and (3) by Fcγ-receptors (FcγRs) leads to the release of interleukin 1β 
(IL-1β), which then induces neutrophil-attracting chemokines, for example, CXCL1, CXCL5, and CCL9, from resident tissue cells. Additionally, neutrophils participate 
in their own recruitment by releasing the chemokine CXCL2 (CXCR2 ligand) and to a lesser extent, CCL3 (CCR1 ligand). (4) IL-1β, and other pro-inflammatory 
cytokines, mediates the release of G-CSF locally in the joint, leading to neutrophil mobilization. (5) Leukocyte, for example, neutrophil, recruitment into the joint is 
facilitated by their LFA-1 binding to its ligands (ICAM1, ICAM2, and JAM-A) expressed on the activated vascular endothelium; Ly6C− blood monocytes are also 
recruited (not shown). (6) Cartilage loss in the inflamed joint is mediated by, for example, IL-1β and macrophage-derived macrophage migration inhibitory factor 
(MIF). (7) Bone erosion upon osteoclast activation by RANK ligand/RANK interaction and release of MIF; MMP8 can protect against bone erosion and arthritis. (8) 
Both TNF and the prostaglandin, PGI2, are produced in the joint and either directly or indirectly mediate pain.
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ultimately bone destruction (19). When addressing the impact of 
the inhibitory FcγRIIB, it was first observed that mice lacking this 
receptor developed arthritis similar to wild-type (WT) mice (6); 
however, three later studies demonstrated an enhanced disease 
progression in FcγRIIB KO mice compared to WT mice, indicat-
ing that this inhibitory Fc receptor has an immunosuppressive 
role in the model (13, 17, 20). In conclusion, these results reveal 
that in the K/BxN STA model FcγRIII is the dominant activating 
Fc receptor, FcγRIV is contributing to a minor extent, and FcγRII 
has an inhibitory role in disease development.
As an indication of the importance of Fc receptors in arthritis, 
intravenous immunoglobulin (IVIG) is widely used as a thera-
peutic strategy for suppression of autoantibody-triggered inflam-
mation in a variety of clinical settings. The immunoglobulins are 
administered in a dose of 1–2 g/kg, and their anti-inflammatory 
effect has been proposed to be the result of several different 
mechanisms (21). In the K/BxN STA model, IVIG has been 
shown to suppress the progression of arthritis indicating that Fc 
receptors are important; however, the mechanisms of action have 
been the subject of disagreement (20–23). First, the mechanism 
behind the immunosuppression was reported to be induced by 
CSF-1-dependent macrophages, which by acting as “sensors” 
for the Fc fragments of IVIG, lead to the induction of FcγRIIB 
expression on CSF-1-independent “effector” macrophages at 
the site of inflammation, thereby raising the threshold for their 
activation by ICs (20). The immunoregulatory effect of IVIG has 
also been investigated in immune thrombocytopenia in mice and 
was shown, as in the K/BxN STA model, to result in an induc-
tion of FcγRIIB on splenic macrophages, thereby preventing 
FcγRIII-mediated clearance of IgG-opsonized platelets (24). 
Later, the anti-inflammatory effect was claimed to result from 
the presence of sialylated IgGs which are IgGs with sialic acid 
bound to glycan on their Fc region (23). These sialylated IgGs 
were shown to bind to the C-type lectin receptor SIGN-R1 on 
regulatory myeloid cells resulting in IL-33 release, which in 
turn stimulated IL-4 secretion from basophils; this IL-4 further 
promoted expression of the inhibitory Fc receptor, FcγRIIB, 
on effector macrophages (23). The same group further showed 
that IVIG or sialylated Fcs activated and expanded regulatory 
T cells in mice injected with K/BxN serum (22). However, the 
importance of sialylation has been questioned by the finding 
that removal of sialic acid residues by neuraminidase did not 
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affect the suppression of K/BxN STA by IVIG (21); furthermore, 
the depletion of basophils did not abrogate the immunosup-
pression exerted by IVIG (21). The reason for the discrepancy 
between these results is currently unknown; however, it could 
be due to differences in, for example, the source of IVIG, route 
of administration, mouse strain, or experimental setup.
THe eFFeCTOR PHASe OF THe K/BxN 
STA MODeL
The essential link in the K/BxN STA model between antibody-
dependent components, such as ICs, complement, and Fc recep-
tors, and arthritis progression, is the activation of innate effector 
cells such as neutrophils, macrophages, and possibly mast cells. 
The main features of what we have termed for convenience the 
“effector phase” of the K/BxN STA model, involving the main 
effector cells and their responses, are depicted in the literature-
based schematic in Figure 2 and are summarized below.
Neutrophils
Neutrophils are readily activated by ICs and play an important 
role in the induction of arthritis in the K/BxN STA model. Their 
essential role was illustrated by Wipke et al. (25), who showed that 
mice depleted of neutrophils failed to develop arthritis  –  even 
neutrophil depletion after the onset of arthritis could reverse 
disease (25). This study used the neutrophil-depleting anti-
Ly6G/C (Gr-1) mAb (clone RB6.8C5). However, the use of this 
antibody was recently challenged as it is thought to deplete not 
only LyG+ neutrophils but also a fraction of the Ly6C+ monocytes 
and macrophages (26). Specific depletion with anti-Ly6G mAb 
(clone 1A8) confirmed a role for neutrophils in the model and 
also showed that non-depleting doses of anti-Ly6G mAb (clone 
1A8) attenuated progression of arthritis due to blockade of neu-
trophil migration into the joint (27). A crucial role of neutrophils 
was further supported by the observation that Gfi-1 KO mice, 
which have a selective defect in their ability to generate mature 
neutrophils, were resistant to arthritis (28).
To further understand the role of neutrophils and how they 
contribute to the induction of arthritis, different neutrophil-
related effector mechanisms have been investigated, including the 
neutrophil-derived leukotriene B4 (LTB4) and its receptor, BLT1. 
LTB4 is a highly potent lipid chemoattractant produced by cells 
of the innate immune system (for example, neutrophils, mac-
rophages, and mast cells). BLT1 is expressed on neutrophils and 
induces chemotaxis and adhesion in response to LTB4 (29, 30). It 
appeared that the arthritis progression in the K/BxN STA model 
was critically dependent on the generation of neutrophil-derived 
LTB4 (31), while neutrophil expression of BLT1 was required for 
arthritis generation as well as chemokine production, suggesting 
that neutrophils recruit other neutrophils in an autocrine manner 
(32). On further examination, BLT1-expression on neutrophils 
was found crucial for their release of the pro-inflammatory 
cytokine, IL-1β, into the joint which induced the production 
of neutrophil-active chemokines, for example, CXCL1, CXCL5, 
and CCL9, from resident tissue cells of the joint (33) (the role 
and impact of IL-1 β in the progression of arthritis in the K/BxN 
STA model will be discussed in further detail later). Moreover, 
neutrophils could directly participate in their own recruitment 
by expressing the CXCR2 ligand, CXCL2, and to a lesser extent 
the CCR1 ligand, CCL3 (33). Recruitment of neutrophils was 
demonstrated to be dependent on their expression of CXCR2 
and partly of CCR1 (33, 34). Recently, the link between release 
of LTB4 and IL-1β from neutrophils and the requirement for C5a 
receptor (C5aR) and FcγR was addressed. It was demonstrated 
that C5aR- and FcγR activation on neutrophils were necessary 
for the initiation and progression of arthritis, and that C5aR acti-
vation of neutrophils was required for their LTB4 release, while 
FcγR engagement mediated IL-1β release (35) (complement 
activation is discussed below and in Figure 2). Activation of the 
two receptors occurred independently from each other without 
any cross-regulation between the two receptor classes. This is a 
unique observation compared to other models of autoantibody-
induced inflammation where C5aR signaling is thought to set 
the threshold for subsequent sustained activation of FcγRs on 
resident tissue immune cells (36). The importance of neutrophil 
expression of FcγR and C5aR as well as their release of LTB4 and 
IL-1β in the K/BxN STA model was confirmed by Monach et al. 
(28). Furthermore, it was shown that C5aR and FcγR on mast 
cells did not contribute significantly to arthritis (35). Some of 
these neutrophil-dependent cascades are depicted in Figure 2.
That FcγR-expression on neutrophils is of crucial importance 
for the recognition of ICs was further addressed through the use 
of the spleen tyrosine kinase (Syk)-deficient mouse strain. Syk is 
required for signaling through FcγRs, integrins, and other scav-
enger receptors by using ITAMs to initiate intracellular signaling. 
First, it was shown that mice lacking Syk in all hematopoietic 
lineages were resistant to disease in the K/BxN STA model (37). 
Second, specific deletion of Syk in neutrophils was sufficient to 
block the initiation of arthritis, which emphasizes the impor-
tance of FcγR signaling in neutrophils after engagement with 
ICs (38). Furthermore, we have recently shown that granulocyte 
colony-stimulating factor (G-CSF), possibly produced from 
IL-1β activation of a resident cell population, is a pivotal driver 
of the disease progression in the K/BxN STA model and possibly 
acts, in part, by regulating neutrophil numbers in the circulation 
(39) (Figure 2).
In conclusion, it is evident that neutrophils are a pivotal cell 
type in the K/BxN STA model and play an essential role in pro-
gression of arthritis. In addition, release of LTB4 and IL-1β ampli-
fies arthritis by driving the ongoing recruitment of neutrophils.
Macrophages
Macrophages are present in high numbers in the inflamed 
joint tissue in RA, and activation of macrophage FcγRs by ICs 
at the site of inflammation has been demonstrated to be crucial 
in the pathogenesis of an immune complex-induced arthritis 
(ICA) model (40). In the K/BxN STA model, the importance 
of macrophages has been demonstrated by depletion studies 
showing that a lack of macrophages resulted in complete resist-
ance to arthritis (41). Importantly, subsequent studies showed 
that arthritis could be induced in macrophage-depleted mice 
by reconstitution with peritoneal macrophages, hence confirm-
ing a key role for macrophages (41). However, it has also been 
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shown that K/BxN serum-induced arthritis is independent of 
CSF-1-dependent macrophages since op/op mice, which lack 
CSF-1, were fully susceptible to arthritis (20). This suggests that 
CSF-1-independent macrophages are the effector macrophages 
in this model. Moreover, a recent study by Misharin et al. (42) 
demonstrated that non-classical Ly6C− blood monocytes were 
recruited to the joint during inflammation in the K/BxN STA 
model where they gave rise to inflammatory macrophages, a 
subtype known as M1 macrophages, and were shown to be crucial 
for development of arthritis (42). Additionally, they showed that 
tissue-resident macrophages in the joint played an important role 
in maintaining joint integrity and resolution of inflammation 
and that they thereby belong to the M2 subtype of macrophages 
(42). Interestingly, their data further suggested that the recruited 
macrophages initially expressed a complex set of both M1 and 
M2 genes followed by a shift toward a more M2 phenotype where 
they, together with the tissue-resident macrophages, attenuated 
the severity of arthritis (42). Taken together, these data suggest 
that circulating Ly6C− non-classical monocytes are recruited to 
the joint in the initiation phase of arthritis, where they orchestrate 
both the development and resolution of the joint inflammation.
The role of granulocyte–macrophage colony-stimulating fac-
tor (GM-CSF) has also been examined in the K/BxN STA model 
(43). GM-CSF is considered to be an important differentiation/
activation factor for macrophages and granulocytes and is also 
a pro-inflammatory mediator (43), with encouraging RA trials 
targeting it or its receptor having been completed (44). Its impor-
tance in arthritis progression was illustrated by the observation 
that in the K/BxN STA model, both GM-CSF KO mice and WT 
mice treated with anti-GM-CSF mAb showed less severe arthritis 
but with a similar time of onset compared to WT control mice 
(43). This was suggested to be a consequence of a reduced number 
of monocytes in the circulation and a decline in the number of 
synovial macrophages. The data indicated that in the absence 
of GM-CSF, the early neutrophil-mediated response was still 
present, whereas later, the macrophage-driven response was 
defective (43). Another aspect of the role of macrophages in the 
K/BxN STA model has been revealed through studying the effect 
of IVIG treatment as described previously (20). It was shown 
that IVIG protected against arthritis induced by K/BxN serum 
through a macrophage-specific induction of FcγRIIB expression 
at the site of inflammation, which raised the threshold for their 
activation by ICs (20).
Taken together, these results suggest that macrophages consti-
tute an important cell type in the K/BxN STA model.
Mast Cells
The role of mast cells in the K/BxN STA model has been contro-
versial mainly due to the different KO strains used in the various 
studies. Insights into the role of mast cells in many inflammatory 
responses relies predominately on a mouse strain deficient in 
mast cells due to a mutation in the gene encoding the receptor 
tyrosine kinase Kit, referred to as the white-spotted (W) Kit allele 
(45). The K/BxN STA model was initially induced in two versions 
of this strain, the mast cell-deficient KitW/W-v strain and the mast 
cell-deficient Kit-ligand (Kitl)-mutated KitlSl/Sl-d strain (46). Both 
strains displayed little or no clinical or histologic signs of arthritis, 
and transfer of mast cells into both strains restored their ability 
to develop arthritis (46). It was also shown that mast cells in the 
initiation phase of the disease were activated through FcγRIII, 
which led to release of IL-1 (47), and arthritis could be suppressed 
by preventing the activation-induced degranulation of mast cells 
by treatment with the cAMP-inducing agent, salbutamol (48). 
Another way that mast cells might drive arthritis was proposed 
to be through the release of tryptase/heparin complexes, which 
were shown to induce the expression of the neutrophil chemoat-
tractants, CXCL1, CXCL5, and CXCL8, in cultured fibroblast-like 
synoviocytes (49). Recently, the use of the mast-cell-deficient 
KitW/W-v-strain has been questioned, since it also shows defects in 
many other cell lineages, such as red blood cells and neutrophils 
(45). When K/BxN STA arthritis in the KitW/W-v-strain was com-
pared with another mast cell-deficient strain, the KitW-Sh-strain, it 
was found that arthritis did not develop in the KitW/W-v-strain but 
that the KitW-sh-strain was fully susceptible. This was explained by 
the neutropenia found in the KitW/W-v-strain but not in the KitW-
sh-strain (18, 38). A dispensable role for mast cells was confirmed 
by the use of a non-kit mutated mast-cell-deficient mouse strain, 
the Cpa3cre/+-mouse, which developed arthritis and, besides a 
lack of mast cells, display a normal immune system (45). The 
discrepancy between arthritis-susceptible Cpa3cre/+-mice and 
arthritis-resistant KitW/W-v-mice suggests an important role for Kit 
in this model. Also, since transfer of mast cells rendered KitW/W-v-
mice susceptible to arthritis (46), it is possible that mast cells have 
pro-pathogenic effects when Kit is missing. In combination, these 
experiments suggest that the previous conclusion regarding the 
importance of mast cells in the K/BxN STA model could be based 
on a misinterpretation of the lack of arthritis in the KitW/W-v-strain. 
Mast cells might contribute, but based on the recent study in the 
mast cell-deficient Cpa3cre/+-strain (45), they appear dispensable.
Natural Killer T Cells
A role for natural killer (NK) T cells in the K/BxN STA model 
was suggested by the observation that arthritis was attenuated in 
CD1d KO and Jα281 KO mice, both deficient in NKT cells (50). 
The mechanism was thought to involve NKT-mediated suppres-
sion of transforming growth factor β1 (TGF-β1) production in 
the joint tissue, which in turn was dependent on release of IL-4 
and interferon γ (IFNγ) from the NKT cells (51). Furthermore, it 
was shown that CD1d KO mice exhibited less severe arthritis and 
that arthritis could only be restored with transfer of NKT cells 
from WT mice and not with transfer of cells from FcγR KO mice. 
These findings indicate that binding of IgG to FcγRIII on NKT 
cells in the joint induces their activation and participation in the 
induction of arthritis (50).
Complement
Development of arthritis in the K/BxN STA model involves 
activation of the complement cascade. It is believed that the 
alternative pathway is important, since mice lacking comple-
ment factor B did not develop arthritis (16). The classical 
pathway or the mannose-binding pathway is not thought to 
be relevant, since transfer of K/BxN sera to mice deficient in 
C1q, C4, and mannose-binding-protein A (MBP-A) resulted 
in normal arthritis development (16). This conclusion was 
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further supported by Solomon et al. (52) who showed that mice 
deficient in C4 or the complement receptors 1 and 2, all compo-
nents of the classical pathway, were susceptible to K/BxN STA 
(52). All three pathways of the complement system lead to the 
generation of C3, which has been shown to be indispensable for 
arthritis induction, thus emphasizing the general importance 
of complement activation in this model (16, 53); in contrast, 
the C3-receptor seems to be dispensable (16). C3 deposits 
have been found locally in the arthritic joints (9, 16), and it 
has been suggested that during the inflammatory response, C3 
is produced by parenchymal cells distant from the joint and 
transported to the joints via the circulation (53). In addition, it 
has been shown that circulating C3 is necessary and sufficient 
for arthritis induction (53). Downstream of C3, the complement 
cascade, leads to activation of C5 that is a central mediator in 
the complement network. In the joints of the K/BxN STA model, 
the alternative complement pathway is activated by the anti-
G6PI/G6PI ICs, leading to C3 cleavage and generation of C5 
(Figure 2). The importance of C5 in the K/BxN STA model was 
demonstrated by the fact that C5 KO mice showed no signs of 
disease (16). This was further confirmed by blockade of C5 with 
anti-C5 mAb, which both prevented disease by treatment prior 
to onset and reversed ongoing disease when injected several 
days after arthritis onset (16). C5 is cleaved by C5 convertase 
into the soluble component, C5a, and the C5b fragment that 
remains bound to the cell surface and initiates the formation 
of the membrane attack complex, the final step of complement 
activation. Formation of the membrane attack complex is not 
required in the K/BxN STA model since C6 deficiency (a com-
ponent of the complex) did not influence disease progression 
(16). In contrast, C5a is crucial for the development of arthritis 
illustrated by the fact that C5a–C5aR KO mice were completely 
resistant to arthritis (16). C5a functions as a chemoattractant 
and inducer of acute inflammation, for example, by activating 
neutrophils and mast cells, stimulating endothelial cells to 
express P-selectin and increasing vascular permeability (3). 
Since antibodies generally activate complement through C1q 
and the classical pathway, it was a surprise that this pathway 
was not involved in driving the disease. However, the dominant 
isotype in anti-G6PI antibodies is the IgG1-subclass (11) and, 
since mouse IgG1 is a weak activator of C1q, a component of 
the classical pathway (54), it may explain why the alternative 
pathway is the one important for arthritis induction in the K/
BxN STA model. Additionally, multimerized IgG1 is efficient 
in activating FcγRIII, which is also an important driver of the 
inflammatory response in the model, as described above (11).
Pro-inflammatory Mediators
Pro-inflammatory cytokines, such as TNF, IL-1, and IL-6, are 
pathogenic drivers in both RA and in many mouse models of 
arthritis; however, the impact of each cytokine on the disease pro-
gression can differ from patient to patient (55) and from model to 
model (56). In the K/BxN STA model, studies have indicated that 
TNF, IL-1β, and IL-6 were released in the inflamed joint (57), but 
a role for TNF could not initially be proven (58). Subsequently, the 
significance of different selected cytokines was studied in further 
detail by Ji et al. (57) who induced the K/BxN STA in a panel of 
mouse strains deficient in one or more inflammatory cytokines 
or their receptors. These results demonstrated a critical role for 
IL-1, since no clinical signs of disease were observed after transfer 
of K/BxN serum into IL-1R-deficient mice, in which both IL-1α- 
and IL-1β-mediated signaling are blocked. In relation to IL-1, it 
should also be mentioned that IL-1 receptor antagonist, which is 
a well-known anti-inflammatory mediator, controlled articular 
inflammation during the acute phase of K/BxN STA (59). The 
results obtained for TNF involvement in the model were mixed, 
since arthritis developed in one-third of the TNF-deficient mice, 
indicating that TNF is an important, but dispensable, driver of 
disease development (57). In contrast to TNF and IL-1, IL-6 did 
not play a role in driving the inflammatory response (57). This 
suggests that in the K/BxN STA model, IL-1 signaling is crucial 
(Figure 2), TNF plays an important but partial, role, and IL-6 is 
completely dispensable.
The recently discovered IL-17 family of cytokines, especially 
IL-17A and IL-17F, which are the most homologous members of 
the family, has been shown to be implicated in the pathogenesis 
of many autoimmune diseases including RA (60, 61). They have 
also been investigated in the K/BxN STA model. First, it was 
shown that administration of anti-IL-17A mAb did not exert any 
effect on arthritis progression (62). Later, it was found that mice 
deficient in IL-17 receptor subunit A were protected from the 
serum-induced arthritis, while recently, it was further demon-
strated that IL-17A KO mice exhibited reduced arthritis (63). The 
same study additionally showed that neutrophils are an essential 
source of IL-17 in the model (63). It has further been found that 
local administration of IL-17 via intra-articular injection of an 
adenovirus vector increased the severity of arthritis in the K/BxN 
STA model (64). The discrepancy between the anti-IL-17 mAb 
study and mice deficient in IL-17A or IL-17 receptor subunit A 
might be explained by insufficient antibody dosing or incomplete 
blocking of IL-17 arising from the tight interaction between effec-
tor cells.
In addition to increased levels of pro-inflammatory cytokines, 
high levels of prostaglandins (PGs) are also found in RA patients. 
They are lipid mediators that, besides having a role in many 
physiologic activities, also play an important role in pathologic 
inflammation (65). In the K/BxN STA model, high levels of 
PGE2, as well as the stable metabolite of PGI2, 6-keto-PGF1α, 
were found in inflamed joints, although only PGI2 appeared 
to be indispensable for arthritis development (65) (Figure  2). 
Furthermore, it was demonstrated that arthritis was reduced by 
pharmacological inhibition of PG synthesis by administration 
of a potent inhibitor of both cyclooxygenase (COX) 1 and 2. 
Interestingly, it was additionally shown that even though both 
COX isoforms were found in the inflamed joints in the model, 
only COX1 contributed substantially to disease (65). Inhibition 
of COX1 and/or COX2 is the mechanism of action behind the 
immunosuppressive effect of non-steroidal anti-inflammatory 
drugs (NSAIDs) that have been used frequently for amelioration 
of symptoms in RA patients (66).
Toll-Like Receptors
Toll-like receptors (TLRs) are a group of receptors that serve 
to recognize pathogen-associated molecular patterns (PAMPs), 
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which often comprise microbial products such as lipopolysac-
charide (LPS) and peptidoglycans. When one of these ligands 
binds to TLRs on cells of the innate immune system, it leads to 
a range of responses, including the release of different cytokines 
and activation of APCs (67). The TLRs differ in their extracel-
lular structure from the receptors for IL-1 and IL-18; however, 
they share the same intracellular signaling pathway, which 
includes myeloid differentiation factor 88 (MyD88) (68). In 
the K/BxN STA model, the role of TLR4 was first investigated. 
It was shown that arthritis progression in TLR4 KO mice had a 
similar initiation phase but was not sustained compared to WT 
mice, suggesting that TLR4 plays a role in the later phase in the 
model (69). Additionally, the same study showed that MyD88 is 
a key molecule and confirmed the essential role of IL-1 since no 
arthritis was observed in either MyD88- or IL-1R KO mice (69). 
Interestingly, LPS, a TLR4 ligand, circumvented the requirement 
for IL-1R signaling (69). However, recent studies reported that 
TLR4 KO mice exhibited either a similar progression of arthritis 
(70, 71) or a reduced arthritis even in the early induction phase 
(72) compared to WT mice. These discrepancies demonstrate 
that the impact of TLR4 on arthritis development in the K/BxN 
STA model varies from study to study and that further studies are 
therefore needed to clarify its role.
The role of another TLR and its ligands in the K/BxN STA 
model has been investigated by Wu et al. (73) who, surprisingly, 
discovered that certain unmethylated DNA CpG motifs (CpGs), 
with their signaling being mediated through TLR9, were able 
to inhibit arthritis. This inhibition relied on cells of the innate 
immune system and, specifically, on crosstalk between dendritic 
cells (DCs) and NK cells. It was suggested that CpGs bind to 
DCs via TLR9, which in return release IL-12 that further 
stimulates NK cells to produce IFNγ. IFNγ subsequently inhibits 
neutrophil migration into the joint (73). These observations 
describe a potential anti-inflammatory role for both CpGs and 
IFNγ in this model underlining the complexity of the innate 
effector mechanisms driving the pathogenesis. Additionally, an 
inhibitory role has been suggested for TLR2, which was shown 
to regulate arthritis in the model by controlling the inhibitory 
FcγRIIB on macrophages (71). Finally, a recent study showed 
that both TLR3 KO and TLR7 KO mice developed reduced K/
BxN serum-induced arthritis (74) and that the transcription fac-
tor, interferon regulatory factor 5 (IRF5), contributed to disease 
progression by mediating pro-inflammatory cytokine produc-
tion, mainly that of IL-1β generated downstream of TLR3 and 
TLR7 (74).
Taken together, these studies suggest that TLR3, TLR7, and 
possibly TLR4 play a pro-inflammatory role in the K/BxN STA 
model, while TLR9 and TLR2 mediate an anti-inflammatory 
effect.
iNTeGRiNS
Leukocyte infiltration into the synovial tissue is a crucial step 
in the pathogenesis of inflammatory arthritis and involves a 
range of different integrins and their ligands. The β2 integrins 
are heterodimeric cell proteins consisting of a common β-chain 
(CD18) that pairs with one of four α-chains: αL (CD11a), αM 
(CD11b), αX (CD11c), or αD (CD11d). Ligands for CD11a/
CD18 (LFA-1) include ICAM-1, -2, -3, and junctional adhesion 
molecule (JAM)-A (75), while ICAM-1 and iC3b are ligands for 
CD11b/CD18 (Mac-1, CR3) (76). In the K/BxN STA model, it 
was demonstrated that β2-deficient mice were resistant to arthritis 
and that CD11a α-chain (LFA-1) was critical for this process (77). 
Moreover, blockade of LFA-1 with an anti-LFA-1 mAb reduced 
the already ongoing inflammation, and functional blockade of 
its counter-receptors, ICAM-1, ICAM-2, and JAM-A, provided 
a reduction, but not complete amelioration, of arthritis (77). 
It was also shown that ICAM-1, ICAM-2, and JAM-A were 
mainly expressed by the vascular endothelium, while LFA-1 was 
expressed on leukocytes within the synovial lining and within 
the inflammatory synovial fluid (77). This study did not inves-
tigate which subtype of leukocytes expressed LFA-1; however, 
another study subsequently demonstrated that LFA-1 expression 
on neutrophils was crucial for arthritis development in the K/
BxN STA model (28). It is reasonable to consider that LFA-1 
expression on monocytes/macrophages might also contribute 
to arthritis progression. In this context, LFA-1 was shown not 
to be important for monocyte migration in an acute murine 
peritonitis model, suggesting that LFA-1 does not play a role 
in infiltration of monocytes into inflamed tissue (78). However, 
whether this is the same for the K/BxN STA model should be 
examined.
In conclusion, recruitment of leukocytes into the joints 
and the ensuing arthritis in the K/BxN STA model seem to be 
dependent on the expression of LFA-1 on leukocytes, especially 
neutrophils, and the binding to its ligands, ICAM-1, ICAM-2, 
and JAM-A, expressed on the activated vascular endothelium 
(Figure 2).
DiSeASe MANiFeSTATiONS
Cartilage Loss and Bone erosion
Cartilage loss is a well-studied pathological manifestation 
of arthritis in the K/BxN STA model (57, 79). IL-1β is often a 
crucial mediator of cartilage destruction in arthritis models (80), 
and after induction of K/BxN STA, IL-1R KO mice showed, in 
addition to complete arthritis suppression, no signs of cartilage 
destruction (57), suggesting that IL-1β is a crucial driver of 
cartilage destruction also in this model. Additionally, bone ero-
sion, via osteoclast activation in inflamed joints, is involved in 
the pathogenesis of RA and has also been studied in the K/BxN 
STA model. One of the essential factors for osteoclast differentia-
tion and activation is the receptor activator of nuclear factor-κβ 
ligand (RANKL), and it was shown that RANKL KO mice were 
protected from bone erosion after transfer of K/BxN serum (81) 
(Figure 2). In contrast, a deficiency in matrix metalloproteinase-8 
(MMP8) increased joint inflammation and bone erosion in the 
model, suggesting that MMP8 protects against the inflammatory 
synovitis and bone erosion (79). A cytokine that could also play 
a role in RA is macrophage migration inhibitory factor (MIF) 
(82). It was first demonstrated that this cytokine was essential 
for disease development in the K/BxN STA model since both 
joint inflammation and cartilage destruction were significantly 
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reduced in MIF KO mice (83) (Figure 2). Furthermore, the same 
study demonstrated that adoptive transfer of WT macrophages 
could restore the sensitivity of MIF KO mice to arthritis develop-
ment (83). Recently, it was further demonstrated that MIF KO 
mice transferred with arthritic K/BxN serum, in addition to 
reduced joint inflammation, exhibited markedly reduced bone 
erosion compared to WT mice. It was also shown in vitro that 
MIF facilitated RANKL-induced osteoclastogenesis, which sug-
gests that MIF contributes directly to bone erosion as well as to 
inflammation in arthritis (84) (Figure 2). Taken together, these 
studies suggest that the K/BxN STA model can also be used as 
an animal model, wherein the different mechanisms behind 
bone erosion can be studied in addition to those governing 
cartilage loss.
PAiN
Recently, an increasing focus has been on the interface between 
the immune and nervous systems in inflammatory pain, with pain 
being a clinical symptom with high negative impact on patients 
suffering from different autoimmune diseases and especially RA. 
Pain in RA is difficult to control and often persists after resolu-
tion of joint swelling with anti-inflammatory treatments (85). 
To address the unmet need for pain relief, inflammatory pain 
has lately been investigated in several arthritis models including 
the K/BxN STA model (86, 87). Christianson et al. (86) showed 
that arthritis in the K/BxN STA model led to persistent pain 
with mechanical hypersensitivity not returning to baseline and 
outlasting the inflammation by 2 weeks (86). Moreover, the pain 
was shown in the inflammatory phase to be sensitive to treat-
ment with NSAIDs and etanercept (TNF blocker) (Figure  2), 
and this was not the case in the post-inflammatory phase (86). 
Furthermore, the same group showed that during the persistent 
pain seen after resolution of inflammation, spinal TLR4 played 
an important role (70).
An interesting aspect of pain is the involvement of capsaicin-
sensitive neurons that not only can mediate pain but also contrib-
ute to inflammatory processes by release of neuropeptides such 
as substance P and calcitonin-gene-related peptide (CGRP) (88). 
In the K/BxN STA model, it was demonstrated that in the early 
phase, capsaicin-sensitive neurons played an anti-inflammatory 
role, while in the later phase (10 days post-serum injection), they 
contributed to mechanical hyperalgesia (88). Furthermore, the 
neuropeptide, neuromedin U, which has pro-inflammatory activ-
ity, was shown to promote arthritis in the K/BxN STA model (89). 
The effect of denervation on arthritis progression has also been 
explored in the K/BxN STA model. Interestingly, it was found that 
denervation of one limb prior to the serum transfer protected that 
limb from arthritis via an impact on the microvasculature. The 
joint-localized vascular leak that normally causes swelling and 
edema in the affected joint was compromised in the denervated 
limbs (90). This finding underlines the fact that arthritis, even in 
a rather simple model system as the K/BxN STA model, results 
from complex interactions between the nervous, immune, and 
vascular systems.
Overall, these recent studies within pain suggest that the K/
BxN STA model is useful for the exploration of pain mechanisms 
and could be a potential model to explore novel pain-modulating 
treatment strategies for RA.
A COMPARiSON OF THe K/BxN STA 
MODeL wiTH OTHeR ARTHRiTiS 
MODeLS
Collagen Antibody-induced Arthritis Model
Among the many different mouse models of arthritis, the K/BxN 
STA model is most similar to the collagen antibody-induced 
arthritis (CAIA) model. The main similarities and differences 
between the features of the CAIA and K/BxN STA models are 
listed in Table  1. In the former model, arthritis develops after 
administration of a defined cocktail of anti-collagen type II mAb 
(anti-CII mAb), most often together with LPS (91). When LPS 
is administered with the antibody cocktail, it enhances the inci-
dence and severity of the disease and thereby reduces the amount 
of mAb required to induce arthritis. Both models represent the 
effector phase of arthritis, work in many mouse strains, and have 
a similar time scale. Both the CAIA and K/BxN STA models are 
driven by antibodies and the formation of ICs (91), and both 
can be induced in T cell- and B cell-deficient mice (4, 92, 93). In 
both models, ICs initiate the inflammatory response either via 
activation of the complement system or by direct engagement and 
activation of Fc receptor-bearing immune cells (91). As to the role 
of Fc receptors, the two models also share similar dependencies 
since CAIA mice lacking the general FcγR-chain were highly 
resistant to arthritis, but FcγRIII-deficient mice were only partially 
resistant (94), an observation also seen in the K/BxN STA model 
(16). Additionally, complement activation and the downstream 
effects of C5a and C5aR are key factors in the pathogenesis of 
arthritis in both models (16, 95, 96). As in the K/BxN STA model 
(16), the alternative complement activation pathway has been 
suggested to be the dominant pathway for inflammation and joint 
destruction in the CAIA model (97–99). However, in the CAIA 
model, the classical pathway additionally seemed to participate 
in complement activation, which indicates that both pathways 
might play a role (98), an observation different from that in the 
K/BxN model. This difference could be explained by the fact that 
IgG1 is the dominant isotype of the anti-G6PI antibodies (11), 
whereas IgG2a and IgG2b are the most widely used for the induc-
tion of CAIA (93). Murine IgG2a, IgG2b, and IgG3 isotypes have 
been shown to activate the classical pathway, whereas IgG1 has 
been suggested to activate the alternative pathway (54).
As in the K/BxN STA model, neutrophils play an essential 
role in the CAIA model and were indispensable both for the 
development and maintenance of arthritis (96). With regard to 
effector cytokines, both TNF and IL-1β have been shown to be the 
major effector cytokines in CAIA, and blockade of either of these 
cytokines ameliorated the disease, whereas IL-6 blockade had no 
effect (92). Hence, TNF seems to be more crucial in the CAIA 
model than in the K/BxN model where, as mentioned, divergent 
results were obtained after neutralizing TNF (57). Another 
cytokine that has been shown to play different roles in the two 
models is IL-4. It was reported to be an important cytokine in the 
CAIA model, and its neutralization greatly reduced the severity 
TABLe 1 | Similarities and differences between the K/BxN STA, CAiA, and CiA models.
Feature K/BxN STA model CAiA model CiA model
Phase(s) Effector Effector Immunization and effector
Susceptible strains Multiple strains (6) Multiple strains (100) DBA1, B10Q, B10.QRIII, and C57BL/6  
(less severe) (101)
Time to termination 10–15 days normally (102) 10–15 days normally (91) 5–6 weeks (101)
Immunization (involvement of  
T- and B-cells)
No (4) No (93) Yes (101)
Antigen G6PI (2) Collagen II (91) Collagen II (101)
Immunostimulatory components None (102) LPS (91) CFA (103)
Autoantibodies Main drivers – ICs formed  
systemically and in the joint (9)
Main drivers – ICs formed in  
the joint (12)
Yes (104)
Isotype of autoantibodies IgG1 (11) •	 IgG2a
•	 IgG2b	(93)
IgG2a (104)








Complement system •	 C5aR (16)
•	 Alternative pathway (16)
•	 C5aR (95)
•	 Alternative and classical  
pathways (98)
•	 C5aR (107)
•	 Alternative and classical  
pathways (108)
Important immune cells •	 Neutrophils (25)
•	 Macrophages (41)
•	 Mast cells? (45, 46)
•	 Neutrophils (96) •	 Neutrophils (109)
•	 Macrophages (110)
•	 T cells (101)
•	 B cells (101)




•	 MIF (83, 84)
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of the disease (111), whereas IL-4 was shown to play no role in 
the K/BxN model (115).
The most significant difference between the two models is 
the specificity of the antibodies driving the disease. In the CAIA 
model, the antibodies are anti-CII mAb (91), whereas the K/
BxN STA model is driven by arthritogenic serum containing 
polyclonal antibodies directed toward G6PI (3). This difference, 
among other aspects, leads to different localization of the respec-
tive antibodies in the joints. Both types of antibodies bind to 
the cartilage surface (10, 116); however, the anti-CII mAb also 
penetrate the cartilage (117). Anti-G6PI serum is more effective 
at inducing arthritis than anti-CII mAb as illustrated by the fact 
that the K/BxN STA model does not need the co-injection of LPS 
as the CAIA model does, and a lower dose of purified anti-G6PI 
IgGs is required to induce arthritis compared to the dose of anti-
CII mAb routinely used (11).
Another important difference between the two models is the 
way the antibodies enter the joints. In the K/BxN STA model, ICs 
are formed systemically due to the fact that G6PI is ubiquitously 
present (9) (Figure 1). As mentioned, the systemic ICs activate 
inflammatory cells, such as neutrophils, which subsequently 
release mediators that increase the vascular permeability, thereby 
giving ICs and antibodies access to the joint (Figure 1). In CAIA 
model, the collagen II (CII) antigen is mainly present in the joint, 
and ICs cannot be formed systemically (12), which means that 
the anti-CII mAb given systemically do not readily localize in 
the joints without any additional trigger. Therefore, LPS or a high 
dose of antibody is needed to ensure that the anti-CII mAb enter 
the joints (12). Overall, despite many similarities between the two 
models, differences also exist such that each model can be used to 
inform on different aspects of arthritis progression.
Collagen-induced Arthritis Model
The CIA model is one of the most widely used animal models for 
RA and shares many similarities with it. It is, therefore, relevant 
to highlight the similarities and differences between the CIA and 
K/BxN STA models and the advantages of each model. The main 
similarities and differences between the features of the CIA and 
K/BxN STA models are also listed in Table  1. The CIA model 
is induced by immunization of susceptible mouse strains, such 
as DBA/1, B10.Q, and B.10RIII, with CII in complete Freund’s 
adjuvant (CFA) (103). However, it can also be established in 
C57BL/6 mice, thereby increasing the range of KO mice that can 
be studied, although the incidence and severity are less than in 
the DBA/1 or B10.RIII strains (101). Typically, chicken or bovine 
CII is used. The mice can be boosted with CII emulsified in 
incomplete Freund’s adjuvant (IFA) 3 weeks later; however, this 
is usually only necessary when using specific types of collagen 
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such as α1(II) chains or purified cyanogen bromide fragments 
of CII (101). Additionally, occasionally LPS is given around the 
time of the boost to induce the disease to occur more rapidly and 
with less variability in onset (118). Normally, arthritis appears 
3–5  weeks after immunization and usually peaks by week 6 
(101). It presents as a polyarthritis most prominently in the 
limbs and characterized by inflammatory synovial infiltration, 
cartilage and bone erosion, and synovial hyperplasia similar to 
RA (119). Generally, susceptibility has been linked to strains 
that have MHC class II I-Aq and I-Ar haplotypes; however, it 
is evident that many mouse strains have variable degrees of 
susceptibility to CIA (119). The biggest difference between 
K/BxN STA and CIA is of course that CIA is the result of an 
active immunization, while arthritis in the K/BxN STA model is 
induced by passive transfer of autoantibodies. Since an immuni-
zation takes place in the induction phase of CIA, arthritis in this 
model is dependent on stimulation of collagen-specific T cells 
and the production of high titers of autoantibodies specific for 
CII by B cells (101). As mentioned, in the K/BxN STA model, 
both T cells and B cells are dispensable (4). However, similar 
to what is the case in the K/BxN STA model (25, 41), both 
neutrophils (109) and macrophages (110) have been shown to 
be important cell types in the CIA model. With regard to the 
role of Fc receptors, the two models show similar dependencies 
since mice lacking the general FcγR-chain were highly resistant 
to CIA (105) and FcγRIII-deficient mice were partially resistant 
(106). Additionally, FcγRII-deficient mice exhibited increased 
arthritis, suggesting an inhibitory role of this FcRII in CIA (105) 
as for the K/BxN STA model (16). Like the CAIA model, both 
the classical and alternative complement pathways have been 
shown to be important in the CIA model (108) and, like in the 
K/BxN STA model (14), C5a and C5aR are key factors in the 
pathogenesis of the CIA model (107).
The two models share the involvement of autoantibodies, 
although the specificity of the autoantibodies varies between the 
two. In the CIA model, the antibodies are directed against CII, 
while in the K/BxN STA model, the antibodies are anti-G6PI. 
Moreover, in the CIA model, the autoantibodies predominantly 
belong to the IgG2a subclass (104), while in the K/BxN STA 
model, they mainly consist of IgG1 (11). With respect to the 
involvement of cytokines, TNF (80), IL-1β (80), G-CSF (109), 
GM-CSF (112), IL-6 (113), and IL-17 (114) are all important 
drivers in the pathogenesis in CIA, while IL-4 has been shown 
to mediate a suppressive effect (120). In the K/BxN STA model, 
it appears that IL-1β (57) and G-CSF (39) are crucial for arthritis 
progression, TNF (57) and GM-CSF (43) have a partial role, and 
both IL-6 (57) and IL-4 (115) play no role.
A major practical advantage of the K/BxN STA model over the 
CIA model is that it induces a robust inflammatory response in 
a range of different mouse strains with 100% incidence and with 
a similar onset. As mentioned previously, the CIA model, on the 
other hand, induces a robust response mainly in susceptible strains, 
such as DBA1, B10.Q, and B10.QRIII, while in C57BL/6 mice, the 
incidence and severity are less pronounced with a variable time of 
onset (101). Moreover, the CIA model runs for 5–6 weeks, while 
the K/BxN STA model is normally terminated 10–15 days after 
serum injection. This means that with the K/BxN STA model, an 
answer to a potential question can be obtained much quicker than 
what is the case with the CIA model. Furthermore, the K/BxN 
STA model is independent of an immunostimulatory component, 
such as CFA, which induces a severe stimulation of the innate 
immune system.
Another important difference between the models is that the 
CIA model represents both the priming and effector phases of 
arthritis and therefore mimics more features of RA than the K/
BxN STA model; nonetheless, since the K/BxN STA model only 
represents the effector phase, one of its advantages is that it can 
be used to study the biology of this phase. The above discussion 
indicates that even though the CIA model often is the first choice 
for a murine model for RA, the K/BxN STA model does offer 
some advantages and can be a valuable supplement to the CIA 
model.
THe K/BxN STA MODeL AS A  
MODeL FOR RA
The K/BxN STA model is a valuable tool in understanding 
the pathogenic mechanisms behind autoantibody-driven 
arthritis. However, it is essential to consider in what aspects 
the K/BxN STA model resembles RA and where it differs. The 
main similarities and differences between the features of the K/
BxN STA model and RA are listed in Table 2. When looking 
at the clinical manifestations and histopathological findings, 
it is evident that this murine arthritis exhibits many features 
similar to RA such as leukocyte invasion, synovitis, pannus 
formation, cartilage and bone destruction, and remodeling of 
the joint (4). However, the progression of arthritis in the K/
BxN STA model is more aggressive developing over a few days, 
whereas the development of RA disease is a very long process 
with a peak incidence between 30 and 50 years of age (121). 
When considering the disease drivers, arthritis in the K/BxN 
STA model is solely mediated by autoantibodies, while in RA, 
even though autoantibodies are present and known to partici-
pate in the pathogenesis, the disease is additionally driven by 
other mechanisms involving, for example, CD4 T cells (122). 
An important role for antibodies in RA is, nevertheless, sug-
gested by the success of anti-CD20 therapy (91). Moreover, 
autoantibodies of several different specificities have been found 
in RA patients, including antibodies against citrullinated filag-
grin, the Fc portion of IgG [rheumatoid factor (RF)], keratin, 
chondrocyte gp39, and heat-shock protein 60 (123). Anti-
citrullinated filaggrin antibodies have been shown to be useful 
as a prognostic marker in patients with early RA (124), while 
in general, the anti-citrullinated protein antibodies (ACPA) are 
found in 60% of RA patients and are believed to be a critical 
hallmark in the pathogenesis of RA (125). Moreover, anti-type 
II collagen antibodies may contribute to disease development 
even though they are not primary drivers of disease (123). RF 
is found in 80% of RA patients, and patients with a positive test 
result for RF in blood have more severe clinical disease and 
complications than seronegative patients (126, 127), although 
the pathophysiological role of RF in RA is still unclear. Of note, 
RF is not present in the K/BxN STA model (126).
TABLe 2 | Similarities and differences between the K/BxN STA and RA 
models.
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Given the essential role of anti-G6PI antibodies in the K/BxN 
STA model, antibody titers to G6PI have also been investigated 
in RA patients, however with conflicting results. Initially, it was 
reported that 64% of RA patients had high levels of anti-G6PI 
antibodies, which were significantly different from healthy 
controls (132), but subsequent studies could not reproduce these 
findings (133–136). A later study suggested that autoantibodies 
to G6PI were associated with the occurrence of extra-articular 
complications, such as Felty’s syndrome characterized by neutro-
penia and an enlarged spleen (137); another study showed that 
autoantibodies to G6PI were not unique to patients with RA but 
were found in many patients with inflammatory arthritis (138). 
These results indicate that G6PI might be one of the several 
autoantigens able to serve as a target for autoantibodies in RA, 
but their pathogenic and diagnostic relevance is currently not 
clear. In this context, G6PI has recently been shown to promote 
proliferation and to inhibit apoptosis in fibroblast-like synovio-
cytes from RA patients (139). Despite the uncertain relevance of 
the different types of autoantibodies, it is likely that, as in the 
K/BxN STA model, autoantibodies in RA drive the inflammatory 
response by IC formation and deposition, complement activation 
as well as activation of Fc receptors on innate immune cells such 
as neutrophils, macrophages and mast cells (122). However, in 
contrast to disease progression relying entirely on autoantibodies 
and their activation of innate immune cells as found in the K/
BxN STA model, RA is driven by complex interactions between a 
range of different cell types from both the innate and the adaptive 
immune systems, such as T cells, B cells, macrophages, DCs, and 
neutrophils (55).
With regard to disease mediators, TNF is an important media-
tor in many, but not all, cases of RA, as shown by the success of 
TNF blockade in treating the disease. In contrast, neutralizing 
IL-1 in clinical settings has been shown to have only a limited 
effect (140). As mentioned, in the K/BxN STA model, IL-1 is 
absolutely required for arthritis development, and TNF appears 
to play an important, but partial, role in the disease pathogenesis 
(57). Additionally, blockade of GM-CSF or its receptor are cur-
rently being tested in RA trials with encouraging results (44), and 
GM-CSF has also been shown to be an important cytokine in 
the K/BxN STA model (43). The crucial role of macrophages and 
neutrophils in the K/BxN STA model (25, 41) and the fact that 
both cell types are found in increased numbers in the inflamed 
synovia in RA patients (55) suggest that they are also likely 
important cell types in RA.
As mentioned previously, the most severe symptom frequently 
reported in RA patients is pain, which can persist after the reso-
lution of joint swelling following anti-inflammatory treatment 
(85). Arthritis in the K/BxN STA model led to persistent pain 
with mechanical hypersensitivity, unlike the joint swelling, not 
returning to baseline but outlasting the inflammation by 2 weeks 
(86). Moreover, the pain was in the inflammatory phase shown 
to be sensitive to treatment with NSAIDs and etanercept (TNF 
blocker) (86), suggesting that the K/BxN STA model might be 
useful for the exploration of the mechanisms and novel treatment 
strategies for RA pain.
Current treatment strategies for RA include NSAIDs, gluco-
corticoids, disease-modifying anti-rheumatic drugs (DMARDs), 
such as methotrexate, and biologic response modifiers, for 
example, the blockade of TNF and IL-6 (66). When considering 
the relevance of the K/BxN STA model as a tool to identify drug 
candidates with potential therapeutic effect in RA, it is noticeable 
that several of the approved drugs to treat RA have also been 
shown to have immunosuppressive effects in the K/BxN STA 
model. Besides the already mentioned effect of blocking TNF, 
glucocorticoids, which are widely used in RA, also suppress 
progression of arthritis (128, 129). Additionally, abrogation of 
arthritis was obtained with inhibition of COX1 and COX2 by 
treatment with NSAIDs (65). Finally, the widely used DMARD 
for RA, methotrexate (130), as well as another DMARD, the 
calcineurin inhibitor, Tacrolimus (131), had a therapeutic effect 
in the model. This indicates that the model can have a predictive 
value in the preclinical screening of drug candidates for RA.
In summary, the K/BxN STA model provides a useful tool for 
studying certain aspects of RA including autoantibodies, comple-
ment, ICs, Fc receptors, and innate cell types, such as neutrophils 
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and macrophages. The increasing focus on autoantibodies and 
especially ACPA in the pathogenesis in RA potentially raises 
the relevance of the K/BxN STA model as the one to study how 
autoantibodies drive autoimmune disease. RA is a heterogeneous 
disease involving multiple different immunological pathways and 
accumulation of multiple autoantibody specificities, which differ 
from patient to patient (66). Therefore, it is not possible to find an 
animal model that covers all phases and aspects of RA. Thus, as 
for any animal model, the K/BxN STA model does not encompass 
all of the features of RA, but mimics several facets of the effector 
phase. A useful exercise would be to create a “pathogenesis map” 
outlining the current knowledge of RA (and other types of arthri-
tis) and align the various animal models according to the specific 
aspect/subset of the disease that each of them reflects. This “map” 
would facilitate choosing the most appropriate model to address 
a given question or to study a particular pathway (141, 142). In 
such a “map,” the K/BxN STA model would be highly relevant as 
a model to study the effector phase of RA and how autoantibodies 
drive joint inflammation.
CONCLUSiON
As an arthritis model, the K/BxN STA model has some obvious 
advantages. First, it has a rapid onset beginning 2–3 days after 
transfer of serum with 100% incidence in genetically identical 
animals. The arthritis is very robust and reproducible, even 
though minor inter-individual variability can be seen. Second, 
it can be induced in a wide range of strain backgrounds and 
therefore also in different KO strains to study the importance 
of different disease mediators. Furthermore, the model is inde-
pendent of immunostimulatory components, such as LPS and 
CFA. Even though G6PI might not be an essential autoantigen 
in RA, the K/BxN STA model is a useful tool to understand how 
autoantibodies, in general, drive the progression of arthritis by 
interacting with different downstream components of the innate 
immune system. A further advantage of the K/BxN STA model 
is that it provides an opportunity to study only the effector phase 
of arthritis without involving the priming phase of the immune 
response. Finally, the model has also proven useful for the study 
of arthritic pain. Taken together, these features make the K/BxN 
STA model a relevant one for RA and, even though not discussed, 
other arthritides; it is also a potentially valuable tool for the 
preclinical screening of new therapeutic targets. Although the 
model has been characterized to a great extent, many aspects of 
arthritis and pain development, including the roles of regulatory 
components, different chemokines, and other pro-inflammatory 
cytokines, are still unknown and need to be addressed.
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